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Purpose: Stereotactic body radiotherapy (SBRT) has emerged as an effective treatment for localized
prostate cancer. However, prostate-speciﬁc antigen (PSA) kinetics after SBRT has not been well charac-
terized. The purpose of the current study is to assess the kinetics of PSA for low- and intermediate-risk
prostate cancer patients treated with SBRT using Cyberknife as both monotherapy and boost after whole
pelvic radiotherapy (WPRT) in the absence of androgen deprivation therapy.
Methods: A total of 61 patients with low- and intermediated-risk prostate cancer treated with SBRT as
monotherapy (36.25 Gy in 5 fractions in 32 patients) and SBRT (21 Gy in 3 fractions in 29 patients) boost
combined with WPRT (45 Gy in 25 fractions). Patients were excluded if they failed therapy by the
Phoenix deﬁnition or had androgen deprivation therapy. PSA nadir and rate of change in PSA over time
(slope) were calculated and compared.
Results: With a median follow-up of 52.4 months (range, 14e74 months), for SBRT monotherapy, the
median PSA nadir was 0.31 ng/mL (range, 0.04e1.15 ng/mL) and slopes were e0.41 ng/mL/mo, e0.17 ng/
mL/mo, e0.12 ng/mL/mo, and e0.09 ng/mL/mo, respectively, for durations of 1 year, 2 years, 3 years, and
4 years postradiotherapy. Similarly, for SBRT boost after WPRT, the median PSA nadir was 0.34 ng/mL
(range, 0.04e1.44 ng/mL) and slopes were e0.53 ng/mL/mo, e0.25 ng/mL/mo, e0.14 ng/mL/mo, and
e0.09 ng/mL/mo, respectively. The median nadir and slopes of SBRT monotherapy did not differ
signiﬁcantly from those of SBRT boost after WPRT. Benign PSA bounces were common in 30.4% of all
cohorts, and the median time to PSA bounce was 12 months (range, 6e25 months).
Conclusions: In this report of low- and intermediate-risk prostate cancer patients, an initial period of
rapid PSA decline was followed by a slow decline, which resulted in a lower PSA nadir. The PSA kinetics of
SBRT monotherapy appears to be comparable to those achieved with SBRT boost with WPRT.
Copyright © 2015 Asian Paciﬁc Prostate Society, Published by Elsevier. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Prostate cancer is the most common cancer and the second
leading cause of death among men in the United States,1 and its
incidence rates in Korea, although relatively lower than those in
western nations, continue to increase.2 At present, intensity-
modulated radiotherapy (IMRT) is the standard of care in radical
radiotherapy for prostate cancer.3 In IMRT delivery, accuracy is
critically important as steep dose gradients may increase the risk ofOncology, Inha University
206, Shinheung-dong 3 Ga,
im).
ciﬁc Prostate Society, Published bgeographical miss.4 Cyberknife (Accuray Inc., Sunnyvale, CA, USA) is
one of the tools used for hypofractionated stereotactic body
radiotherapy (SBRT) and real-time image guidance to account for
intrafraction prostatic motion. Advanced techniques of Cyberknife
allow high doses of radiation to be delivered precisely to the target
while sparing the surrounding healthy tissue.5
Accumulating recent clinical evidence has demonstrated that
the a/b ratios of prostate cancermay be around 2 Gy, which is lower
than that of the surrounding normal tissue.6,7 The hypofractionated
radiotherapy schema may improve the biochemical control of
prostate cancer without increasing toxicities associated with late-
responding tissue.6 Analogously, hypofractionation with Cyber-
knife has demonstrated excellent efﬁcacy and toxicity proﬁles as
both monotherapy and boost after whole pelvic radiotherapy
(WPRT) for localized prostate cancer.8e14y Elsevier. This is an open access article under the CC BY-NC-ND license (http://
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for prostate cancer and available for monitoring response to
treatment. In patients without androgen deprivation therapy
(ADT), analysis of PSA kinetics after treatment may reveal the
biologic effect of radiation on prostate cancer. The changes of PSA
after radical prostatectomy, external beam radiotherapy, and
brachytherapy have been researched extensively.15 A lower PSA
nadir and a rapid decline in PSA after treatment have been related
to improved clinical outcome.16e19 Unfortunately, kinetics of PSA
decline following SBRT using Cyberknife remains poorly under-
stood, and there are only a few reports fromwestern countries.20,21
It is necessary to elucidate the kinetics of SBRT in Asian population.
The purpose of the current study is to assess the kinetics of PSA for
low- and intermediate-risk prostate cancer patients treated with
SBRT using Cyberknife as both monotherapy and boost after WPRT
in the absence of ADT.
2. Materials and methods
2.1. Patient characteristics
From 2008 to 2014, 61 patients newly diagnosed with low-
and intermediate-risk (National Comprehensive Cancer Network
deﬁnition) localized prostate cancer treated with SBRT using the
Cyberknife robotic radiosurgery system (Accuray Inc.) were
enrolled in this retrospective analysis. The treatment modality
was chosen by the patient after extensive discussion of various
treatment options, including surgery, SBRT, and IMRT. Of 61 pa-
tients, 32 were treated with SBRT as monotherapy and 29
received SBRT boost after WPRT. All patients had histologically
conﬁrmed primary adenocarcinoma of the prostate. None of
these patients had received any other local or systemic primary
treatment of prostate cancer. Prior transurethral resection of the
prostate for urinary symptom relief was allowed. Patients were
stratiﬁed according to 2.2014 National Comprehensive Cancer
Network risk stratiﬁcation guidelines.22 This study was approved
by the Ethical Committee for Clinical Trials of our institution, and
the retrospective data were prospectively collected from our
institutional database.
In order to assess PSA kinetics in response to radiotherapy alone,
patients were excluded if they failed therapy by the Phoenix deﬁ-
nition.23 All included patients had at least 1 year of follow-up. PSA
bounce was deﬁned as an absolute increase in PSA level of 0.2 ng/
mL from the previous level, followed by a subsequent decrease.24
Toxicity was documented at follow-up visits using the Radiation
Therapy Oncology Group scale.
2.2. SBRT treatment planning and delivery
Four or more gold ﬁducial markers were implanted trans-
perineally into the prostate. After 7 days, patients underwent
magnetic resonance imaging and thin-cut computed tomography
scan. Fused computed tomography and magnetic resonance im-
ages were used for treatment planning. The prostate, seminal
vesicles, rectum, bladder, penile bulb, and bowel were contoured.
The clinical target volume (CTV) included the prostate and prox-
imal seminal vesicles. The planning target volume (PTV) equaled
the CTV expanded by 3 mm posteriorly and 5 mm in all other
dimensions. A prescription dose of 36.25 Gy, delivered in ﬁve
fractions, was prescribed to the PTV. The prescription dose
covered at least 95% of the PTV, normalized to the 75e85%
isodose line [median homogeneity index of 1.27 (range,
1.24e1.41)]. The rectal doseevolume goals were as follows: <50%
of the rectal volume receiving 50% of the prescribed dose, <20%
receiving 80% of the dose, <10% receiving 90% dose, and <5%receiving 100% of the dose. Treatments were given over 5
consecutive days. All SBRT treatment plans were generated on
MultiPlan (version 2.2.0; Accuray Inc.).
2.3. WPRT and SBRT boost treatment planning and delivery
The prostate gland, seminal vesicles, and area of radiographic
extracapsular extension were deﬁned as CTV1. CTV2 included the
external iliac nodes, internal iliac nodes, presacral nodes, and
obturator nodes following the Radiation Therapy Oncology Group
consensus.15 PTV1 was extended 7 mm beyond the CTV1 in all
directions, except in the posterior direction, wherein it was
extended 5 mm. PTV2 was extended 7 mm in all directions. The
prescription dose of WPRT was 45 Gy, which was administered in
25 fractions. A minimum of 95% of the prescription dose was
assured to cover 100% of the PTV. All WPRT treatment plans were
generated on a Varian Eclipse treatment planning system (version
8.8.6; Varian Medical Systems, Palo Alto, CA, USA).
In SBRT boost planning, the prostate gland, seminal vesicles, and
area of radiographic extracapsular extension were deﬁned as the
CTV, which was the same as that of the WPRT treatment plans. The
PTV extended 5 mm beyond the CTV in all directions, except in the
posterior direction, wherein it was extended 3 mm. A prescription
boost dose of 21 Gy, delivered in three fractions, was prescribed to
the PTV. The prescription dose covered at least 95% of the PTV,
normalized to the 75e85% isodose line ;median homogeneity index
of 1.29 (range, 1.21e1.43)]. The rectal doseevolume goals were as
follows: <50% of the rectal volume receiving 50% of the prescribed
dose, <20% receiving 80% of the dose, <10% receiving 90% dose, and
<5% receiving 100% of the dose. Treatments were given over 3
consecutive days.
2.4. Statistical analysis
To eliminate the effect of differing follow-up durations between
SBRT monotherapy and SBRT boost after WPRT, we calculated the
rate of change in PSA over time intervals from the completion of
radiotherapy to 1 year, 2 years, 3 years, and 4 years post-treatment.
The slope of PSA decline (ng/mL/mo) was calculated as the
regression coefﬁcient in a linear regression model for each indi-
vidual.25 The t test was performed to compare slopes of PSA and
other mean values and analysis of variance in continuous variables.
3. Results
All patients completed the treatment. Sixty-one patients with a
median 52.4-month (range, 14e74 months) follow-up were
analyzed. The pretreatment median PSA level was 7.68 ng/mL
(range, 3.45e19.50 ng/mL). Patient characteristics are summarized
in Table 1.
Fig. 1 shows PSA changes over time, with a different rate of PSA
decline for each time interval since the end of radiotherapy. To
investigate the PSA kinetics after radiotherapy, the rate of PSA
decline (slope) was calculated for four intervals following radio-
therapy (0e1 year, 0e2 years, 0e3 years, and 0e4 years). The slope
for all cohorts wasmaximal in the 1st year, but tapered off quickly in
the following years, with median values of e0.43 ng/mL/mo,
e0.22 ng/mL/mo, e0.13 ng/mL/mo, and e0.09 ng/mL/mo for du-
rations of 1 year, 2 years, 3 years, and 4 years after radiotherapy,
respectively. Distribution of the slope for SBRT monotherapy did
not differ from that of the SBRT boost and WPRT through the years
(Table 2). Owing to relatively homogenous inclusion criteria, there
were no signiﬁcant differences in the comparison of the rate of PSA
decline by the Gleason score (6 vs. 7) and pretreatment PSA (10
vs. >10).
Table 2
Comparison of the rate of PSA decline of SBRTmonotherapy and SBRT boostþWPRT
cohort.
Through year SBRT monotherapy SBRT boost þWPRT P
1 e0.41 (e0.19, 0.04) e0.53 (e0.21, 0.06) 0.35
2 e0.17 (e0.11, 0.03) e0.25 (e0.14, 0.04) 0.48
3 e0.12 (e0.03, 0.09) e0.14 (e0.05, 0.03) 0.73
4 e0.09 (e0.04, 0.01) e0.09 (e0.04, 0.01) 0.96
PSA, prostateespeciﬁc antigen; SBRT, stereotactic body radiotherapy; WPRT, whole
pelvis radiotherapy.
Fig. 2. PSA nadir by SBRT as monotherapy and SBRT boost after WPRT. PSA, prostate-
speciﬁc antigen; SBRT, stereotactic body radiotherapy; WPRT, whole pelvic
radiotherapy.
Table 1





Median age (range) 66.5 (56e77) 68.7 (60e78)
ECOG
0 22 (68.8%) 18 (62.1%)
1 10 (31.2%) 11 (37.9%)
T stage
T1eT2a 10 (31.3%) 6 (20.7%)
T2beT2c 22 (68.7%) 23 (79.3%)
Gleason score
6 16 (50%) 5 (17.2%)
7 16 (50%) 24 (82.8%)
Pretreatment PSA (ng/mL)
Mean (range) 7.68 (3.45e14.90) 9.04 (6.76e19.50)
<10 25 (78.1%) 21 (72.4%)
10e20 7 (21.9%) 8 (27.6%)
NCCN risk group
Low 9 (28.1%) 0 (0%)
Intermediate 23 (71.9%) 29 (100%)
ECOG, Eastern Cooperative Oncology Group; NCCN, National Comprehensive Cancer
Network; PSA, prostateespeciﬁc antigen; SBRT, stereotactic body radiotherapy;
WPRT, whole pelvis radiotherapy.
Prostate Int 3 (2015) 118e122120The PSA response deﬁned by the PSA nadir was excellent. The
entire cohort achieved a median PSA nadir of 0.32 ng/mL (range,
0.04e1.44 ng/mL). The SBRT monotherapy cohort achieved a me-
dian PSA nadir of 0.31 ng/mL (range, 0.04e1.15 ng/mL) with a
median follow-up of 32.8 months, and the SBRT boost after WPRT
cohort achieved a median PSA nadir of 0.34 ng/mL (range,
0.04e1.44 ng/mL) with amedian follow-up of 33months (Fig. 2 and
Table 3). Benign PSA bounces were common in 30.4% of all cohorts.
The median time to PSA bounce was 12 months (range, 6e25
months). The median height of PSA bounce was 0.3 ng/mL (range,
0.21e1.39 ng/mL). Patients with PSA bounces had lower pretreat-
ment PSA levels (9.26 ng/mL vs. 6.43 ng/mL, P¼ 0.005) and were
associate with the low-risk group (P¼ 0.07).
The prevalent acute complaints after radiotherapy were urinary
frequency and rectal pain; acute Grade II genitourinary (GU) and
gastrointestinal (GI) toxicity were seen in 19.7% and 14.8% of pa-
tients, respectively. Late Grade II GU and GI toxicities were observed
in 11.5% and 8.2% of patients, respectively. No Grade III GI or GU
toxicities occurred.Fig. 1. PSA changes after SBRT as monotherapy and SBRT boost after WPRT. PSA,
prostate-speciﬁc antigen; SBRT, stereotactic body radiotherapy; WPRT, whole pelvic
radiotherapy.4. Discussion
In this report, we described the changes in PSA levels in patients
with low- and intermediate-risk prostate cancer treated with SBRT
as monotherapy and SBRT boost after WPRT. The majority of PSA
decline occurred in the 1st year but tapered off quickly in the
following years. Katz et al8 demonstrated that PSA level declines
steadily after treatment, and a very lowmean level of 0.25 ng/mL is
achieved within 4e5 years. Anwar et al20 compared the PSA ki-
netics between hypofractionated SBRT and conventionally frac-
tionated external beam radiotherapy for localized prostate cancer,
and reported that median slopes for SBRT were e0.09 ng/mL/mo,
e0.06 ng/mL/mo, and e0.05 ng/mL/mo, respectively, for durations
of 1 year, 2 years, and 3 years postradiotherapy. In our study, rates
of PSA decline after SBRT as monotherapy and SBRT boost with
WPRT were e0.43 ng/mL/mo, e0.22 ng/mL/mo, e0.13 ng/mL/mo,
and e0.09 ng/mL/mo for durations of 1 year, 2 years, 3years, and 4
years, respectively. Although, a direct comparison with other
studies is not proper, the rate of PSA decline in our study tended to
be more rapid than that in Anwar et al’s20 study; however, theTable 3
PSA kinetics for SBRT monotherapy and SBRT boost and WPRT.
SBRT monotherapy SBRT boost þWPRT
Median PSA nadir (ng/mL) 0.31 (0.04e1.15) 0.34 (0.04e1.44)
PSA nadir  0.5 ng/mL (%) 75.0 75.9
Median time to nadir (mo) 32.8 (9e52) 33 (12e51)
PSA bounce (%) 37.50 27.60
Median PSA bounce (ng/mL) 0.34 (0.21e1.39) 0.26 (0.21e0.58)
Median time to PSA bounce (mo) 13.5 (6e18) 11.5 (6e25)
PSA, prostateespeciﬁc antigen; SBRT, stereotactic body radiotherapy; WPRT, whole
pelvis radiotherapy.
Kim et al / PSA kinetics after SBRT 121median pretreatment PSA level of 7.68 ng/mL in our study was
slightly higher than that of 6.2 ng/mL in the report of Anwar et al.
Shi et al25 described that a lower PSA at diagnosis had a lower PSA
velocity following radiotherapy. However, the difference in the rate
of PSA decline after radiotherapymay be due to underlying biologic
differences between Asian and Western men, but any racial dif-
ferences in PSA kinetics after hypofractionated radiotherapy need
further studies.
Recent clinical evidence has demonstrated that the a/b ratios of
prostate cancer may be around 2 Gy.6,7 SBRT as monotherapy
delivered in ﬁve fractions of 7.25 Gy has a biologic equivalent dose
(BED) of 167.7 Gy, assuming an a/b ratio of 2 (e.g., BED2), and is
comparable to a BED2 of 180 Gy with SBRT boost (3 fractions of
7 Gy) and WPRT (35 fractions of 1.8 Gy). Consistent with dose
escalation trials that have showed a lower PSA nadir with an in-
crease in total dose,26 we expect the SBRT monotherapy and SBRT
boost regimen to produce a similar effect of a lower PSA nadir and
rapid rate decline of PSA. In our study, the rate of PSA decline was
not signiﬁcantly different between SBRT as monotherapy and SBRT.
Lamb et al27 showed that the postradiation nadir PSA is the
strongest indicator. Zelefsky et al28 demonstrated that nadir PSA
values of 1.5 ng/mL at 2 years after radiation therapy for prostate
cancer could predict long-term distant metastases and cause-
speciﬁc mortality. We consider the low nadir of 0.32 ng/mL in our
report as an indication of a favorable outcome despite the limited
follow-up.
In this study, PSA bounce was seen in 30.4% of patients after
SBRT monotherapy and SBRT boost after WPRT with a median time
of 12months. McBride et al11 found that the mean age of thosewho
experienced a bounce was signiﬁcantly lower than those who did
not. Vu et al29 reported that younger age was the only factor that
predicted PSA bounce following SBRT for prostate cancer. Park
et al30 showed that only the pretreatment PSA level was associated
with an increased risk of PSA bounce. However, the pretreatment
PSA level, Gleason score, and low-risk group were associated with
PSA bounce in our study.
Zelefsky et al28 reported on late toxicity using a 81 Gy dose with
IMRT in conventional fractionation. The 8-year actuarial likelihood
of Grade II GI toxicity was 1.6%, and 0.1% of patients experienced
Grade III rectal toxicity. The 8-year likelihood of late Grade II and
III GU toxicities was 9% and 3%, respectively. Our current study
shows a similar proportion of toxicity.
Our study is limited by the retrospective nature of analysis and a
small number of patients. There were no strict protocols for the
clinical decision-making process. Future studies should employ
more comprehensive instruments to assess the effect of prostate
SBRT.
In this report of low- and intermediate-risk prostate cancer
patients, an initial period of rapid PSA decline was followed by a
slow decline, which resulted in a lower PSA nadir. The PSA kinetics
of SBRT monotherapy appears to be comparable to those achieved
with SBRT boost with WPRT. Hypofractionated SBRT as mono-
therapy and SBRT boost combined with WPRT is a promising
treatment option for menwith low- and intermediate-risk prostate
cancer. Continued accrual and follow-up would be necessary to
conﬁrm the biochemical control rate and toxicity proﬁles.
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